A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence
Conditions: Chronic Obstructive Pulmonary Disease; Lung Non-Small Cell Carcinoma; Pneumonia; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8 Interventions: Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Lung Cancer | Pneomococcal Vaccine | Pneumonia | Research | Vaccines